Magic Hour
SoCal Gas
You are here:  Home  >  Central Coast Health Watch  >  Current Article

Amgen settles with AbbVie over Humira biosimilar litigation

By   /   Friday, October 6th, 2017  /   Comments Off on Amgen settles with AbbVie over Humira biosimilar litigation

    Print       Email
Amgen’s settlement with rival AbbVie gives it a timeline for the rollout of a biosimilar that mimics Humira, the world’s best-selling drug, but AbbVie still secured protections for its $16 billion-a-year golden goose. The Thousand Oaks-based company received Food and Drug Administration approval for its Humira biosimilar in September of 2016, and Chicago-based AbbVie filed…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Thousand Oaks approves Caruso apartment complex at The Lakes

Read More →